Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Valneva SE (NASDAQ:VALN) is a French specialty vaccine company founded in 1998 and headquartered in Saint-Herblain, France. The company went public on NASDAQ in May 2021, having previously traded on European exchanges. Valneva focuses on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs, particularly targeting travel-related and emerging infectious diseases. The company has evolved from a pure research and development organization into a commercial-stage biotechnology company with marketed products and a robust pipeline of vaccine candidates in various stages of clinical development.
Latest newsMore news →
The European Medicines Agency validated the Marketing Authorization Application for Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 and will begin its assessment.38d agoValneva SE implemented a restructuring program, with positive effects on income statement and cash flow expected in the second half of 2026.39d agoValneva SE reported its condensed consolidated financial results for the first half of 2026, provided corporate updates, and reaffirmed its financial guidance for 2026.39d ago